<DOC>
	<DOCNO>NCT01114750</DOCNO>
	<brief_summary>A pharmacokinetic study absorption perorally deliver insulin dextran matrix single dose administration .</brief_summary>
	<brief_title>A Study Determine Absorption Peroral Insulin Dextran Matrix ( ORA3 )</brief_title>
	<detailed_description>The study single blind , cross study subject receive single active dose ( 200 IU ) insulin dextran matrix placebo two different experimental day .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Dextrans</mesh_term>
	<criteria>Healthy male subject , age 1840 year . Fasting blood glucose within range 4.06.0 mmol/L Screening , Day 1 dose ≥ 4 mmol/L . However , subject exclude study blood glucose range treatment period start . Body Mass Index ( BMI ) 2027 kg/m2 Medically stable determine history physical examination , include vital sign . Screening laboratory test must within normal range judge clinically significant Principal investigator/Subinvestigator . Negative urine ketoacidosis test ECG include QTcB show clinically significant abnormality acute ischemia Supine BP ≤ 139/89 mm Hg diastolic/systolic , discretion investigator Able adhere study visit schedule , understand comply protocol requirement . Capable give informed consent , must obtain prior screen procedure . Negative laboratory screen Hepatitis B ( HBsAg antiHBc antibody ) , Hepatitis C ( anti HCV ) HIV ( 1 &amp; 2 ) . Willing refrain consume alcohol 48 hour prior dose throughout period sample collection . Not prohibit medication ( See section 8.9 ) , discretion investigator . Current sign symptom severe , progressive uncontrolled renal , hepatic , hematologic , gastrointestinal , endocrine , pulmonary , cardiac , neurologic , cerebral disease , condition increase risk participation trial opinion investigator . Currently know malignancy history malignancy within previous 5 year , exception basal cell squamous cell carcinoma skin excise one year ago evidence recurrence A chronic recurrent infectious disease , include limited , chronic renal infection , chronic chest infection ( bronchiectasis ) , sinusitis , recurrent urinary tract infection ( recurrent pyelonephritis chronic nonremitting cystitis ) , open skin wound , ulcer . Other medical condition , drug treatment significant medical problem would preclude participation clinical trial , opinion investigator , disqualifies subject . Participation clinical trial within prior 3 month History GI surgery ( appendectomy ) know GI motility disorder . History serious infection , include limited hepatitis , pneumonia , pyelonephritis , hospitalize receive intravenous antibiotic infection , previous two month . A recent adult history clinically significant allergic reaction drug . History polyps gastrointestinal tract . Known substance abuse ( drug alcohol ) problem within previous 5 year Alcohol use within 48 hour prior visit study unit . Unable undergo venipuncture study purpose poor tolerability lack easy access . Engaging strenuous exercise ( run weight lift play team sport soccer ) within 48 hour prior visit study unit . Donation plasma within 7 day prior first dose . Donation blood within 3 month prior first dose Difficulty swallow capsule .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>blood glucose</keyword>
	<keyword>blood insulin</keyword>
	<keyword>dextran</keyword>
	<keyword>diabetes</keyword>
	<keyword>hyperglycemia</keyword>
	<keyword>hypoglycemia</keyword>
	<keyword>oral delivery</keyword>
	<keyword>portal delivery</keyword>
</DOC>